Prosecution Insights
Last updated: November 16, 2026
Application No. 17/419,535

Compositions and Methods for Preparing Nucleic Acid Sequencing Libraries Using CRISPR/CAS9 Immobilized on a Solid Support

Final Rejection §112
Filed
Jun 29, 2021
Priority
Jul 12, 2019 — provisional 62/873,609 +1 more
Examiner
RAYMONDA, MATTHEW HAROLD
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Iiiumina Cambridge Limited
OA Round
4 (Final)
40%
Grant Probability
Moderate
5-6
OA Rounds
88%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
6 granted / 15 resolved
-20.0% vs TC avg
Strong +48% interview lift
Without
With
+47.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
34 currently pending
Career history
58
Total Applications
across all art units

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 16, 18, 41, and 51-77 were cancelled earlier in examination. Claim 17, and 40 are newly cancelled. Claims 1, 6, 32, 37, and 46 have been amended. Claims 1 and 37 are independent claims. Claims 1-15,19-39 and 42-50 are pending and under examination. Response to Arguments Rejections Withdrawn The rejection to claims 6 and 37 under 35 U.S.C. § 112(a) for failing to comply with the written description requirement is withdrawn following Applicant’s amendments to the claims. The rejection of claims 17 and 40 under 35 U.S.C. § 112(a) for failing to comply with the enablement requirement is withdrawn following the cancellation of the claims. The rejection of claims 1-8, 10-15, 17, 19-40, and 42-50 under 35 U.S.C. 112(a) for failing to comply with the enablement requirement is withdrawn following Applicant’s amendments to the claims and cancellation of claims 17 and 40. Rejections Maintained The rejection of claims 9, under 35 U.S.C. 112(a) for failing to comply with the enablement requirement is maintained. While the Applicant has amended claims 1 and 37 to comply with the sgRNA length restrictions, the Applicant has not addressed the sgRNA length in regards to claim 9. The rejection of claims 1-16, 19-39, and 42-50 under 35 U.S.C. § 103 as being obvious over Gormley, Zhou, and Jian-Kui is maintained. Applicant's arguments filed 07/10/2026 have been fully considered but they are not persuasive. Applicant acknowledges that Gormley and Zhou are relied on for everything other that the random sgRNA sequence, and that Jian-Kui was applied to supply that feature (see Remarks 07/10/2026, pg. 10). Applicant does not otherwise dispute the Office’s findings regarding Gormley and Zhou or the rationale for combining them. Applicant’s remaining arguments are that (1) Jian-Kui’s sgRNA’s “cannot comprise a pure (AT)n motif” because position 1 is always G, and (2) the Office’s reliance on inherency fails because the presence of (AT)n sequences in a random library is merely statistical. Neither is persuasive. Claim interpretation: Amended claim 1 recites inter alia sgRNAs “comprising randomers and having a length of 5-20 nucleotides, and wherein the sgRNAs comprise (AT)n, wherein n is 5-10.” Claim 37 recites similar language. “Comprise” is an open transitional term that does not exclude additional, unrecited elements (see MPEP 2111.03), and the specification states the same (see Spec. [0134]). The claims recite no position for the (AT)n repeat within the sgRNA, and no limitation that the sgRNA consist only of (AT)n. The specification does not define “randomers” or limit the sgRNAs to a fixed sequence. It describes the sgRNA as chosen to direct non-sequence specific cutting and lists “short randomers” and “sequences of (GC)n or (AT)n” as examples (see Spec [0070]-[0071]). Applicant’s original claim 7 likewise recited that “the sgRNA comprises (GC)n or (AT)n wherein n is 5-20,” using the same open term and no “pure” or “consist of” language. Under the broadest reasonable interpretation, the claimed sgRNAs encompass a randomer population whose members comprise a contiguous (AT)n repeat, with any flanking nucleotides. The “pure (AT)n” argument. Applicant argues that because the first nucleotide in Jian-Kui is always G, Jian-Kui’s sgRNAs cannot comprise a “pure” (AT)n motif. The claims do not recite a “pure” (AT)n motif. The argument is therefore not commensurate with the scope of the claims and arguments not commensurate with the claim language are not persuasive (see MPEP 2145(VI)). Applicant’s reading also conflicts with the claim itself, which requires the sgRNAs “comprising randomers.” An sgRNA that is entirely (AT)n has no randomized positions. If “pure” were required, the claim could not also recite randomers. Under the open construction above, a fixed 5’ G does not prevent an sgRNA from comprising (AT)n. Jian-Kui teaches an sgRNA library in which nucleotide 1 of the 20-nucleotide recognition region is G and nucleotides 2-20 are random (see Example 1, SEQ ID NOs: 1, 3). The first position is fixed to improve T7 transcription efficiency. Applicant’s own characterization concedes that the remaining positions are randomer (see Remarks 07/10/2026, pg. 10). Applicant’s “2-20 bases” paraphrase follows the machine-translated Summary, which is garbled. Example 1 and SEQ ID NO: 3 show position 2-20 as N. The 19 random positions can accommodate a contiguous (AT)n repeat of up to n=9 (e.g., G-(AT)5-N14 through G-(AT)9-N, comprise (AT)n for n=5-9). Those members comprise (AT)n with n within the claimed ranges of 5-1, and a species within a claimed range meets that range (see MPEP 2131.03, 2144.05(I)). The claim does not require n=10 in every embodiment. Jian-Kui’s G-N19 region is also within the claimed length of 5-20 nucleotides. The inherency argument. Applicant correctly states that inherency requires that a feature be necessarily present, not merely possibly present (see MPEP 2112(IV)). That standard is not the one the governs here, for two reasons. First, the rejection does not depend on a probability that a random draw contains (AT)n. Jian-Kui expressly teaches a defined sequence formula, G followed by 19 positions each independently A, C, G, or T, and teaches that this formula yields 419 sgRNA sequences covering the genome (see Jian-Kui, “Contents of the Invention”; Example 1) The (AT)n-containing sequences are members of the disclosed set because they satisfy the disclosed formula, not because they happen to arise from chance. A prior art reference is relevant for everything it teaches, not only its preferred embodiments (see MPEP 2123; In re Susi, 440 F.2d 442, 169 USPQ 423 (CCPA 1971)). A skilled artisan reading Jian-Kui would understand that the library comprises sgRNAs of every sequence of that form, including those with internal (AT)n repeats. Second, Jian-Kui reports that the synthesized library was analyzed by deep sequencing, which showed that the nucleotides were randomly distributed across the target sequence (see Jian-Kui, Example 2; Figs. 8-9). A library synthesized with fully degenerate positions is a mixture in which each position carries all four nucleotide. Members containing a given internal sequence are therefore necessarily part of that mixture, in contrast to a single sampled sequence. Applicant’s further assertion that there is no “teaching or suggestion to specifically select and use sgRNA comprising (AT)n motifs” is also not commensurate with the claims. Claim 1 recites providing a solid support having CRISPR/Cas9 enzymes associated with sgRNAs comprising randomers, wherein the sgRNAs comprise (AT)n. It does not recite selecting (AT)n sgRNAs from a larger set. Applying Jian-Kui’s randomer library as the guide population in the immobilized Cas9 platform of Zhou provides sgRNAs comprising randomers, among which are members comprising (AT)n, as claimed. Combination: One cannot show nonobviousness by attacking references individually where, as here, the rejection is based on a combination (see MPEP 2145; In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981). Applicant acknowledges that Gormley and Zhou supply the remaining limitations. Jian-Kui supplies the randomized sgRNA library, and it would have been obvious to use that library in Zhou’s immobilized Cas9 platform to achieve the unbiased immobilized fragmentation sought in Gormley, with a reasonable expectation of success in light of Jian-Kui’s demonstration of genome-wide random binding and mutation (see Jian-Kui Example 2). Applicants’ arguments are not persuasive, and the rejection is maintained. New Rejections Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1-16, 19-39, and 42-50 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites sgRNA “comprising randomers and having a length of 5-20 nucleotides, and wherein the sgRNAs comprise (AT)., wherein n is 5-10.” Claim 37 recites similar language. The scope of these limitations cannot be determined with reasonable certainty for the following reasons. First, “Randomers” and “(AT)n” are in tension, and the claim does not say how they relate. The specification does not define “randomers.” The term ordinarily denotes sequences in which one or more positions are randomized, so that the sequence is not predetermined. “(AT)n” is a predetermined, defined repeat. The claim does not state whether the (AT)n is within the randomized regio, in addition to it, or in a different portion of the sgRNA. Nor does it state whether each sgRNA comprises (AT)n or only the population does. The specification does not resolve this. It presents “short randomers” and “sequences of (GC)n or (AT)n” as alternative examples of sgRNAs (see Spec. [0071]; see also [0008], [0034]), and it describes the sgRNA as chosen to direct Cas9 in a non-sequence specific manner so that cleavage is random (see Spec. [0070]). A person of ordinary skill in the art could not determine whether the claim covers (a) a randomized population in which some members contain an (AT)n repeat or individual sgRNA each containing both randomized positions and an (AT)n repeat, or a defined (AT)n guide. These readings differ materially in scope. Second, the recited length and repeat count cannot be reconciled for all values. An (AT)n repeat is 2n nucleotides long, so n=5-10 corresponds to 10-20 nucleotides. Where the claim recites a length of 5-20 nucleotides, any sgRNA of 5-9 nucleotides cannot comprise (AT)n at all. Where n is 10, (AT)n occupies 20 nucleotides, the maximum recited length, so an sgRNA of that length comprising (AT)10 has no remaining positions that could be randomized and cannot also comprise randomers. The claim does not indicate which of these combination is intended to be within its scope. Third, the claim is unclear as to what is being measure by “a length of 5-20 nucleotides.” Claim 1 recites “a target region of single guide RNAs (sgRNAs)… having a length of 5-20 nucleotides.” The claim does not make clear whether the length applied to the target region or the randomer portion, and thus does not make clear which region must contain the (AT)n. In regards to claim 9, claim 1 recites that the sgRNAs have a length of 5-20 nucleotides. Claim 9 depends from claim 1 through claims 4 and 6 and recites “wherein the sgRNA is 10-40 nucleotides.” Per claim 6 and Spec. [0007], [0033], [0062], and [0068], “the sgRNA” is the 5’ portion of the first polynucleotide that directs CRISPR/Cas9 enzymes to the target, which is the same element whose length is limited in claim 1. The two ranges overlap only for 10-20 nucleotides. IT therefore unclear whether claim 9 is limited to that overlap or is intended to include lengths of 21-40 nucleotides, which fall outside of claim 1. The claim fails to inform a person of ordinary skill in the art of its scope with reasonable certainty. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew H Raymonda whose telephone number is (703)756-5807. The examiner can normally be reached Monday - Friday 10:00 am - 4:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached at 571-272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW HAROLD RAYMONDA/Examiner, Art Unit 1684 /AARON A PRIEST/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Show 4 earlier events
Aug 06, 2025
Final Rejection mailed — §112
Jan 29, 2026
Request for Continued Examination
Feb 02, 2026
Response after Non-Final Action
Mar 11, 2026
Non-Final Rejection mailed — §112
May 12, 2026
Interview Requested
May 19, 2026
Examiner Interview Summary
Jul 10, 2026
Response Filed
Oct 22, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12753431
Spatially Encoded Biological Assays
3y 0m to grant Granted Oct 06, 2026
Patent 12736458
FLOW CELLS
4y 4m to grant Granted Sep 15, 2026
Patent 12529102
SYSTEMS, METHODS, AND COMPOSITIONS FOR GENERATING MULTI-OMIC INFORMATION FROM SINGLE CELLS
3y 8m to grant Granted Jan 20, 2026
Patent 12480114
Nucleic Acid Library Preparation Using Electrophoresis
4y 5m to grant Granted Nov 25, 2025
Patent 12391975
SYSTEMS AND METHODS FOR TRANSPOSON LOADING
4y 1m to grant Granted Aug 19, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
40%
Grant Probability
88%
With Interview (+47.7%)
High
PTA Risk
Based on 15 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month